NCT05523700Completed
Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)
Source: ClinicalTrials.gov · Last updated 10 Oct 2025
Brief summary (registry, in English)
This study will evaluate the use of a mobile application in improving the patient-reported health outcome measures (PROMIS) for patients diagnosed with advanced stage ovarian, fallopian tube, and primary peritoneal cancer. The application will incorporate clinical data from the patient's medical chart as well as capture patient-reported outcome measures on an ongoing basis to better inform physicians and the care team so that necessary interventions may be implemented.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 9 Aug 2022
- Start date
- 17 Oct 2023
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Ovarian cancer
- NCT number
- NCT05523700
What you commit to
- Study type: Interventional
- Participants enrolled: 10
- From 17 Oct 2023 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent non-gynecologic cancer diagnosis requiring active treatment at enrollment
Other illness
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Age
- Age \<18yo
Other
- Unwilling or unable to adhere to the protocol
- Unwilling or unable to adhere to the informed consent
Who the study is looking for
- Female ≥18 years of age at Screening Visit.
- Diagnosed with ovarian cancer, fallopian tube, or primary peritoneal cancer
- Undergoing active treatment at some point during the study period including chemotherapy, immunotherapy, targeted agent or hormonal therapy. If active treatment has not yet started at time of screening, active treatment must be anticipated to begin within 30 days of enrollment.
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- Access to IOS or Android-based smart phone
Age in the registry: 18 years to 90 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.